Primary Sjögren's syndrome: Pathophysiological, clinical and therapeutic advances

Joint Bone Spine

Volumn 76, Issue 6, 2009, Pages 591-594

  Gottenberg, J E ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

B lymphocytes; Disease activity score; Interferons; Primary; Rituximab; Sj gren's syndrome

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; ESTROGEN; ETANERCEPT; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERFERON REGULATORY FACTOR 5; RITUXIMAB; STAT4 PROTEIN;

B LYMPHOCYTE ACTIVATION; CLINICAL TRIAL; DENDRITIC CELL; DISEASE ACTIVITY; DNA POLYMORPHISM; ENTEROVIRUS; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; HEPATITIS C VIRUS; HUMAN; INNATE IMMUNITY; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; RETROVIRUS; SALIVARY GLAND; SCORING SYSTEM; SHORT SURVEY; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CONTROLLED CLINICAL TRIALS AS TOPIC; HEALTH STATUS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 71249087529     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.09.006     Document Type: Short Survey

References (35)

1. Hjelmervik T.O., Petersen K., Jonassen I., et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy controls. Arthritis Rheum 52 (2005) 1534-1544
2. Gottenberg J.E., Cagnard N., Lucchesi C., et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 103 (2006) 2770-2775
3. Emamian E.S., Leon J.M., Lessard C.J., et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 10 (2009) 285-296 Epub 2009 Apr 30
4. Miceli-Richard C., Comets E., Loiseau P., et al. Association of an IRF-5 gene functional polymorphism with Sjogren's syndrome. Arthritis Rheum 56 (2007) 3989-3994
5. Nordmark G., Kristjansdottir G., Theander E., et al. Additive effects of the major risk alleles of IRF-5 and STAT-4 in primary Sjögren's syndrome. Genes Immun 10 (2009) 68-76 Epub 2008 Dec 18
6. Miceli-Richard C., Gestermann N., Ittah M., et al. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndrome. Arthritis Rheum 60 (2009) 1991-1997
7. Kariuki S.N., Kirou K.A., MacDermott E.J., et al. Cutting edge: autoimmune disease risk variant of STAT-4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 182 (2009) 34-38
8. Ishimaru N., Arakaki R., Yoshida S., et al. Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjögren's syndrome-like autoimmune exocrinopathy. J Exp Med. 205 (2008) 2915-2927 Epub 2008 Nov 17
9. Theander E., Henriksson G., Ljungberg O., et al. Lymphoma and other malignancies in primary Sjogren's syndrome A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65 (2006) 796-803
10. Zintzaras E., Voulgarelis M., and Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: A meta-analysis. Arch Intern Med 165 (2005) 2337-2344
11. Mariette X., Roux S., Zhang J., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 62 (2003) 168-171
12. Daridon C., Devauchelle V., Hutin P., et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 56 (2007) 1134-1144
13. Litinskiy M.B., Nardelli B., Hilbert D.M., et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3 (2002) 822-829
14. Waterman S.A., Gordon T.P., and Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum 43 (2000) 1647-1654
15. Dawson L.J., Fox P.C., and Smith P.M. Sjogren's syndrome - the non-apoptotic model of glandular hypofunction. Rheumatology (Oxford) 45 (2006) 792-798
16. Deshmukh U.S., Nandula S.R., Thimmalapura P.R., et al. Activation of innate immune response through toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med 38 (2009) 42-47
17. Robinson C.P., Yamamoto H., Peck A.B., et al. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 79 (1996) 50-59
18. Gottenberg J.E., Busson M., Loiseau P., et al. In primary Sjogren's syndrome. HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 48 (2003) 2240-2245
19. Seror R, Ravaud P, Bowman S, et al. Eular Sjögren's syndrome disease activity index (ESSDAI): development of a consensus systemic disease activity index in primary Sjögren's syndrome. Ann Rheum Dis 2009 Jun 28 Epub ahead of print.
20. Mariette X., Ravaud P., Steinfeld Set al. Inefficacy of infliximab in primary Sjögren's syndrome. Results of the randomized controlled trial of Remicade in primary Sjögren's syndrome (TRIPSS). Arthritis Rheum 50 (2004) 1270-1276
21. Sankar V., Brennan M.T., Kok M.R., et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50 (2004) 2240-2245
22. Mavragani C.P., Niewold T.B., Moutsopoulos N.M., et al. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 56 (2007) 3995-4004
23. Yao Y., Richman L., Higgs B.W., et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 60 (2009) 1785-1796
24. Gross J.A., Johnston J., Mudri S., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 (2000) 995-999
25. Stohl W., Chatham W., Weisman M., et al. Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), selectively modulates B-cell sub-populations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis Rheum 52 (2005) S444
26. Wallace D.J., Stohl W., Furie Ra, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus eryhtematosus. Arthritis Rheum 61 (2009) 1168-1178
27. Pijpe J., van Imhoff G.W., Spijkervet F.K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52 (2005) 2740-2750
28. Devauchelle-Pensec V., Pennec Y., Morvan J., et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 57 (2007) 310-317
29. Somer B.G., Tsai D.E., Downs L., et al. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 49 (2003) 394-398
30. Voulgarelis M., Giannouli S., Tzioufas A.G., et al. Long term remission of Sjogren's syndrome associated aggressive B-cell non-Hodgkin's lymphomas following combined B-cell depletion therapy and cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). Ann Rheum Dis 65 (2006) 1033-1037
31. Seror R., Sordet C., Guillevin L., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 66 (2007) 351-357
32. Dass S., Bowman S.J., Vital E.M., et al. Reduction of fatigue in Sjogren's syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis 67 (2008) 1541-1544
33. Meijer J., Vissink A., Meiners P.M., et al. Rituximab treatment in primary Sjögren's syndrome: A double-blind placebo controlled trial. Arthritis Rheum 56 (2008) S430 (abstract 713)
34. Steinfeld S.D., Tant L., Burmester G.R., et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8 (2006) R129
35. Gatumu M.K., Skarstein K., Papandile A., et al. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Res Ther 11 (2009) R24 Epub 2009 Feb 18